Exclusive Summary

• Solid Market Foundation: Irbesartan is a core treatment for hypertension and type 2 diabetic nephropathy, with a global patient base exceeding 1 billion, ensuring massive and stable market demand.
• Clear Clinical Value: Listed on the WHO Essential Medicines List and recommended as a first-line therapy in major global hypertension guidelines, ensuring high market acceptance without the need for extensive academic promotion.
• International Quality Recognition: The product is PIC/S GMP certified, which serves as a quality passport for entry into numerous countries and regions like Europe, Southeast Asia, and Australia, significantly simplifying registration and building client trust.
• Ideal Distribution Product: As a mature, off-patent generic, the key to competition is reliable supply and cost-effectiveness, making it a perfect fit for distributors seeking stable sales volume and market share.